Skip to content
Medical Health Aged Care

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus

Tanner Pharma 2 mins read
  • Media:

 


CHARLOTTE, N.C. & LEXINGTON, Mass.--BUSINESS WIRE--

Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT) and balstilimab (BAL). Through a Named Patient Program (NPP), this initiative offers patients with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors the opportunity to access BOT/BAL based on supporting clinical evidence and medical need.

Tanner Pharma will manage access to BOT/BAL for patients in geographies that allow named patient access to investigational medicines. The NPP ensures that patients, in consultation with their physicians, can access BOT/BAL even before regulatory approval, adhering to all ethical and compliance standards.

BOT and BAL are investigational immunotherapies designed to target challenging cancers, including MSS CRC and other tumors historically resistant to immune-based treatments. Clinical outcomes have demonstrated complete pathological responses in neoadjuvant MSS colon cancer patients and durable tumor responses across multiple cancer types. These results establish BOT/BAL as a treatment option with the potential to redefine standards of care for patients with difficult-to-treat cancers.

About Tanner Pharma

Tanner Pharma Group specializes in delivering global access solutions for specialty medicines. Through Named Patient Programs, compassionate use, and expanded access programs, Tanner Pharma connects patients and healthcare providers with essential treatments, prioritizing ethical and regulatory compliance.

About Agenus

Agenus is a pioneering immuno-oncology company dedicated to expanding the benefits of cancer immunotherapy. Founded in 1994, Agenus has a diverse portfolio of immunological agents, including antibody therapeutics, cell therapies, and adjuvants. Headquartered in Lexington, MA, Agenus operates end-to-end development capabilities, from discovery to commercial manufacturing. For more information, visit www.agenusbio.com or follow @agenus_bio.

Information that may be important to investors will be routinely posted on our website and social media channels.

About Botensilimab (BOT)

Botensilimab is a human Fc-enhanced CTLA-4 blocking antibody designed to enhance anti-tumor immune responses, particularly for tumors that are unresponsive to conventional therapies. BOT primes T cells, downregulates regulatory T cells within tumors, and activates myeloid cells to induce long-term immune memory. BOT, used alone or in combination with BAL, has shown promising clinical responses in various cancers.

For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.


Contact details:

Agenus Contact

Investors
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com

Media

Images

TannerPharma_color_logo_hi-res.jpg

Download media

More from this category

  • Medical Health Aged Care
  • 16/03/2025
  • 05:30
Dementia Australia

Join us today for Illawarra Memory Walk & Jog

What: Dementia Australia’s Illawarra Memory Walk & Jog    When: Sunday 16 March from 7:30am   Who: More than 600 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Actress and Dementia Australia Ambassador Jessica Redmayne will MC.   Where: Lang Park, Wollongong   Dementia Australia spokespeople and local residents are available for interview. Photos and video of previous Memory Walk & Jog events for publication are available for use. For more information visit: www.memorywalk.com.au Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living…

  • Contains:
  • Medical Health Aged Care
  • 14/03/2025
  • 17:11
Galderma Group AG

Galderma Successfully Placed an Inaugural EUR 500 Million Single Tranche Eurobond and New Dual Tranche CHF 435 Million CHF Bonds

  ZUG, Switzerland–BUSINESS WIRE– Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION…

  • Contains:
  • Federal Election, Medical Health Aged Care
  • 14/03/2025
  • 15:45
Congress of Aboriginal and Torres Strait Islander Nurses and Midwives (CATSINAM)

SEVEN-POINT PLAN FOR IMMEDIATE EFFECTIVE HEALTH REFORM A Unified Call from Australia’s Peak Nursing and Midwifery Groups

Australia’s peak nursing and midwifery groups are calling on the major parties at this election to commit to immediate and effective reform that will…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.